EUVIMEDEUVIMED entdecken
Crossref

Prognostic Impact of CD56 and CD117 Expression in Newly Diagnosed Multiple Myeloma

S.J. Mohammed, M.M. Mustafa, I.A.I. Agha

Лабораторная диагностика. Восточная Европа · 30.09.2026 · 15 (3(S)) · 128-136

DOI: 10.34883/pi.2026.15.3.058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Лабораторная диагностика. Восточная Европа, online erschienen am 30.09.2026. Verfasst von S.J. Mohammed und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Multiple myeloma (MM) is a clinical condition characterized by clonal expansion of plasma cells that leads to end-organ damage, referred to as a myeloma-defining event, warranting initiation of therapy.

Purpose

To evaluate prognostic impact of CD56 and CD117 expression in newly diagnosed MM. Materials and methods. In this A prospective study, analysis was conducted on multiparametric flow cytometry data obtained from diagnostic bone marrow aspirations of 30 newly diagnosed MM patients who go to Al Hadbaa Blood and BMT hospital and "Ibn Sena" Teaching Hospital in Nineveh Governorate and the data were collected from hematological laboratory. CD56 and CD117 expression levels were analyzed in relation to disease stage and clinical characteristics, with staging classified according to the International Staging System (ISS).

Results

According to ISS staging system 30% of patients are within stage I and 23.4% within stage II and 46.6% within stage III. About 4/30 patients had non secretory MM (normal SPE and immune fixation) and 26/30 had abnormal SPE which 40% is IgG with kappa restriction. About 13/30 of patients were positive for both CD56 and CD117. Comparative analysis between CD56 positive and CD56 negative group subsets using multiple parameters show statistic significant with platelet count which high in CD 56 positive group than negative group while β2M is higher in negative group than positive group. In this study Comparative analysis between CD117 positive and CD117 negative group subsets using multiple parameters show statistic significant with serum Albumin level also high in CD 117 positive group than negative group, Hb and platelet count also high in CD 117 positive group than negative group while β2M is higher in negative group than positive group.

Conclusion

The expression of CD56 and CD117 in MM represents a valuable immunophenotypic biomarker that may help in predicting disease prognosis. Their expression appears to be associated with disease progression and clinical characteristics in MM patients. The expression CD56 and CD117 has been reported to correlate with a more favorable prognosis. However, further large-scale studies are required to clarify the relationship between CD56 and CD117 expression and cytogenetic abnormalities in patients with MM.

Zitieren

APA

Mohammed, S., Mustafa, M., & Agha, I. (2026). Prognostic Impact of CD56 and CD117 Expression in Newly Diagnosed Multiple Myeloma. Лабораторная диагностика. Восточная Европа, 15(3(S)), 128-136. https://doi.org/10.34883/pi.2026.15.3.058

Vancouver

Mohammed S, Mustafa M, Agha I. Prognostic Impact of CD56 and CD117 Expression in Newly Diagnosed Multiple Myeloma. Лабораторная диагностика. Восточная Европа. 2026;15(3(S)):128-136. doi:10.34883/pi.2026.15.3.058

BibTeX
@article{Mohammed2026,
  author = {Mohammed, S.J. and Mustafa, M.M. and Agha, I.A.I.},
  title = {Prognostic Impact of CD56 and CD117 Expression in Newly Diagnosed Multiple Myeloma},
  journal = {Лабораторная диагностика. Восточная Европа},
  year = {2026},
  volume = {15},
  number = {3(S)},
  pages = {128--136},
  doi = {10.34883/pi.2026.15.3.058}
}
Kostenlos starten →